Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

    Cancer Categories
    • Breast,Gastrointestinal (GI),Lung
    Karmanos Trial ID
    • 2024-036
    NCT ID
    • NCT04939610
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Primary Objective:

    • To evaluate the safety and tolerability of [177Lu]Lu-FAP-2286 and determine the RP2D

    Secondary Objectives:

    • To measure the radiation dosimetry of [177Lu]Lu-FAP-2286
    • To determine tumor uptake using [68Ga]Ga-FAP-2286
    • To evaluate tumor uptake of [68Ga]Ga-FAP-2286 as compared to FDG
    • To evaluate the PK of [177Lu]Lu-FAP-2286
    • To evaluate preliminary efficacy of [177Lu]Lu-FAP-2286 in advanced solid tumors
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions